Cornerstone National Bank & Trust Co Reduces Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Cornerstone National Bank & Trust Co lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 60.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 4,545 shares of the medical equipment provider’s stock after selling 7,090 shares during the period. Cornerstone National Bank & Trust Co’s holdings in Zimmer Biomet were worth $409,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. Rakuten Investment Management Inc. bought a new position in Zimmer Biomet in the third quarter valued at about $37,307,000. Sector Gamma AS raised its stake in Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after acquiring an additional 24,847 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Zimmer Biomet by 29.2% in the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after acquiring an additional 13,812 shares during the last quarter. Border to Coast Pensions Partnership Ltd boosted its stake in shares of Zimmer Biomet by 6.5% in the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after purchasing an additional 22,104 shares in the last quarter. Finally, National Pension Service boosted its stake in shares of Zimmer Biomet by 4.5% in the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after purchasing an additional 16,928 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research analyst reports. Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. The Goldman Sachs Group downgraded shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price target for the company. in a report on Friday, January 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $105.95.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $91.27 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $108.29. The company has a 50 day simple moving average of $93.59 and a two-hundred day simple moving average of $93.05. The company has a market capitalization of $17.67 billion, a PE ratio of 25.78, a P/E/G ratio of 1.89 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the previous year, the company earned $2.31 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.39 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 27.12%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.